Physician
CG Medical Associates INC
CG Medical Associates INC was paid $42.16M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.
33Billing provider infoCG MEDICAL ASSOCIATES INC
CINCINNATI, OH 45230
CINCINNATI, OH 45230
33aNPI1982903951assigned 03/16/2011
33bProvider typeFamily Medicine Physician
28Total paid$42.16M
24GClaims1,166,987
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#2 of 739
Median peer was paid$30K
This provider vs. median1,422×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,799 | $2.32M | |
| 2019 | 89,677 | $4.33M | |
| 2020 | 77,779 | $3.86M | |
| 2021 | 153,562 | $5.88M | |
| 2022 | 281,656 | $8.40M | |
| 2023 | 237,652 | $7.55M | |
| 2024incomplete | 269,862 | $9.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 239,094 | 214,946 | $13.85M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 178,107 | 157,112 | $8.09M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 13% | 80,800 | 73,676 | $5.45M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 12% | 98,706 | 90,242 | $5.00M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 8.8% | 123,319 | 109,750 | $3.72M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.6% | 8,008 | 7,360 | $1.54M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.4% | 105,691 | 45,554 | $1.01M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.8% | 75,241 | 67,448 | $768K |
| 99051 | 1.3% | 129,907 | 117,271 | $533K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 6,833 | 6,235 | $277K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 6,862 | 6,182 | $256K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 21,177 | 16,849 | $229K |
70 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,853 | $220K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 9,822 | $214K |
| 99205 | Prolong outpt/office vis | <1% | 1,181 | $99K |
| 87481 | <1% | 2,873 | $99K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,076 | $97K |
| 87653 | <1% | 4,152 | $94K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,762 | $87K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,769 | $85K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,692 | $74K |
| 87529 | <1% | 1,598 | $73K | |
| 87511 | <1% | 2,862 | $60K | |
| 81002 | <1% | 16,782 | $40K | |
| 87641 | <1% | 1,622 | $37K | |
| 81025 | <1% | 3,325 | $19K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,755 | $16K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 154 | $15K |
| 87480 | <1% | 973 | $12K | |
| 99201 | <1% | 264 | $12K | |
| 81003 | <1% | 7,010 | $11K | |
| 87498 | <1% | 458 | $9K | |
| 86580 | <1% | 849 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,520 | $7K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 98 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,319 | $6K |
| 90714 | <1% | 156 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,058 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,920 | $3K |
| 69209 | <1% | 396 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 105 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 120 | $2K |
| 10060 | <1% | 36 | $2K | |
| 99384 | <1% | 31 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 137 | $2K |
| 87428 | <1% | 44 | $1K | |
| 87640 | <1% | 66 | $1K | |
| 12001 | <1% | 13 | $808.20 | |
| 87500 | <1% | 32 | $803.28 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 40 | $736.77 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 62 | $687.90 |
| 93000 | <1% | 52 | $685.55 | |
| 73610 | <1% | 29 | $665.32 | |
| 86328 | <1% | 37 | $603.32 | |
| 69210 | <1% | 32 | $587.74 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 139 | $519.90 |
| 87088 | <1% | 140 | $515.54 | |
| 86308 | <1% | 145 | $494.03 | |
| 73630 | <1% | 27 | $446.16 | |
| 87581 | <1% | 13 | $342.16 | |
| 87486 | <1% | 16 | $334.54 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 246 | $323.46 |
| 87541 | <1% | 15 | $308.22 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 836 | $259.08 |
| 86696 | <1% | 32 | $217.67 | |
| 82962 | <1% | 70 | $210.22 | |
| 73130 | <1% | 12 | $202.80 | |
| 69200 | <1% | 13 | $196.89 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 204 | $180.60 |
| 86803 | <1% | 16 | $145.33 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 234 | $83.63 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16 | $74.53 |
| A6450 | Light compression bandage, elastic, knitted/woven, width greater than or equal to five inches, per yard | <1% | 58 | $49.36 |
| A4565 | Slings | <1% | 12 | $45.00 |
| 86695 | <1% | 30 | $39.56 | |
| S9083 | Global fee urgent care centers | <1% | 209 | $37.20 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 35 | $36.12 |
| 86592 | <1% | 17 | $22.40 | |
| 80305 | <1% | 55 | $20.20 | |
| 76140 | 0% | 19 | $0.00 | |
| 99173 | 0% | 47 | $0.00 | |
| 99000 | 0% | 451 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUPTA, CHETAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Carefirst Urgent Care, LLC | Las Vegas, NV | $1.85M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.